Korea BNC Obtains Chinese Patent for Dexibuprofen Liquid Injection
Predicted impact: Low· Actual: −5.5% vs sector, volume 0.2× normal (5 trading days)
Chinese patent registration for an injectable drug; small, routine and no revenue size given.
BNC Korea한국비엔씨
256840 · KOSDAQ · ₩256840 · 한국비엔씨
₩2,430▼ ₩55 (2.21%)End-of-day · Oct 29, 2026 · End-of-day prices.
Price · 1Y −53.63%
- Market cap
- ₩166B
- Enterprise value
- ₩98B
- P/E
- —
- P/B
- 0.7×
- Dividend yield
- 2.9%
- ROE
- −2.1%
- Net margin
- −5.2%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−60.7% from the high
₩2,050Today: ₩2,395 – ₩2,515₩6,180
Returns
- 1W−8.8%
- 1M−25.9%
- 3M+12.0%
- 6M−38.9%
- YTD−45.8%
- 1Y−53.6%
- Volume today
- 435,823
- 0.1× the 20-day average
- Traded today
- ₩1.1B
- Listed shares
- 68,394,886
- EPS (12 months)
- −₩69
- Earnings yield −2.8%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
- MomentumWeak-29.1% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
BNC Korea stock overview
BNC Korea (한국비엔씨, KRX: 256840) is listed on KOSDAQ, in the Biotech & Pharma sector. The company researches, manufactures, sells and distributes biomedical products centered on bio-healthcare, including hyaluronic acid HA fillers, botulinum toxin pharmaceuticals, collagen-based tissue reinforcement and wound dressing materials, and Derma Cosmetic functional cosmetics, many of which are sold to hospitals and clinics. Its shares closed at ₩2,430 on Oct 29, 2026, down 2.21% on the day, giving it a market value of ₩166B.
Key facts
- Market cap
- ₩166B
- Sector
- Biotech & Pharma
- Latest price change
- −2.21%
- As of
- Oct 29, 2026
- Main business
- The company researches, manufactures, sells and distributes biomedical products centered on bio-healthcare, including hyaluronic acid HA fillers, botulinum toxin pharmaceuticals, collagen-based tissue reinforcement and wound dressing materials, and Derma Cosmetic functional cosmetics, many of which are sold to hospitals and clinics.
Quick answers about BNC Korea
- What does BNC Korea do?
- The company researches, manufactures, sells and distributes biomedical products centered on bio-healthcare, including hyaluronic acid HA fillers, botulinum toxin pharmaceuticals, collagen-based tissue reinforcement and wound dressing materials, and Derma Cosmetic functional cosmetics, many of which are sold to hospitals and clinics. Its consolidated subsidiaries develop and sell aesthetic medical devices and distribute research reagents and testing instruments for biotechnology research, supplying universities, research institutes, hospitals and pharmaceutical companies in Korea and abroad.
- What is the market cap of BNC Korea?
- The market capitalisation of BNC Korea was ₩166B at the close on Oct 29, 2026.
- Who are the largest shareholders of BNC Korea?
- According to the latest official filings, the largest reported holders are Choi Wan-gyu (19.94%, as of Sep 23, 2026); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (1.21%, as of Jul 31, 2026); VANGUARD DEVELOPED MARKETS INDEX FUND (0.74%, as of Jun 30, 2026).
- When is the next earnings report from BNC Korea?
- Korean companies rarely announce results dates in advance. Based on when BNC Korea filed the same report in past years, its next preliminary results is expected between Feb 13, 2026 and Nov 9, 2026.
Company profile
The company researches, manufactures, sells and distributes biomedical products centered on bio-healthcare, including hyaluronic acid HA fillers, botulinum toxin pharmaceuticals, collagen-based tissue reinforcement and wound dressing materials, and Derma Cosmetic functional cosmetics, many of which are sold to hospitals and clinics. Its consolidated subsidiaries develop and sell aesthetic medical devices and distribute research reagents and testing instruments for biotechnology research, supplying universities, research institutes, hospitals and pharmaceutical companies in Korea and abroad.
Written by AI from the company's latest annual report.
- Korean name
- 한국비엔씨
- Sector
- Biotech & Pharma
- CEO
- 최완규
- Founded
- Oct 2016
- Listed
- Dec 2016
- Listed shares
- 68,394,886
- Fiscal year ends
- Month 12
- Website
- www.bnckorea.co.kr
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent news
Recent filings
See all- 5%+ holding reportSep 23, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- 5%+ holding reportJul 13, 2026
- 5%+ holding reportJun 29, 2026
- Insider shareholding reportJun 29, 2026
Titles in Korean until English translations are added.
Also known as: BNC Korea / 한국비엔씨 / 256840 / KRX:256840
Source: KRX statistical information